A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said. ・Genmab assumed sole responsibility for the ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially risky investment. Learn more about STA stock here.

Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.

Old drugs, new ideas. That’s one of the core drivers of using artificial intelligence (AI) for drug development. Researchers using complex AI-fueled methods are now taking aim at what has become a ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...